Last updated: June 12, 2026

KRINTAFEL (tafenoquine) market dynamics and financial trajectory: pricing, uptake drivers, exclusivity and competitive threat

KRINTAFEL’s commercial trajectory is shaped by a narrow, high-acuity use case (relapse prevention of Plasmodium vivax malaria), a constrained eligible patient population, and steady pricing pressure as malaria drug formularies normalize and competitors file generics or alternative regimens. Financial performance has remained sensitive to (1) procurement cycles for government and donor purchasers, (2) geographic mix across malaria-endemic regions, and (3) payer and guideline adoption of tafenoquine relative to primaquine and other 8-aminoquinoline strategies.

The product’s market dynamics are also governed by exclusivity over core tafenoquine IP and any formulation or method-of-use claims tied to dosing and safety management. In practice, the competitive threat is less about broad OTC substitution and more about regulatory and access pathways for lower-cost tafenoquine products or alternative gametocytocides and relapse-prevention regimens, plus local procurement preferences.

What is KRINTAFEL and what drove its commercial ramp?

KRINTAFEL is the brand name for tafenoquine, an 8-aminoquinoline used in malaria. Its market is tied to adoption of tafenoquine in regimens for relapse prevention of P. vivax, where safety management (notably G6PD testing) and clinician familiarity influence real-world uptake.

Key demand drivers

Guideline inclusion and protocol adoption: Commercial pull rises when national malaria programs and major clinical guidelines recommend tafenoquine-based regimens with defined eligibility criteria.
Diagnostic readiness: Uptake depends on availability of G6PD testing before dosing and the operational ability to implement that workflow at scale.
Single-dose convenience versus dosing burden: Where tafenoquine is positioned against multi-day primaquine courses, procurement and adherence dynamics can shift toward tafenoquine.
Procurement cycle timing: Government and donor tenders drive quarterly revenue patterns. Contract timing often dominates “organic” prescribing growth.

Key headwinds

Safety constraints narrow eligible use: G6PD deficiency screening and contraindication frameworks can reduce treatable volumes.
Competing relapse prevention options: Primaquine remains a benchmark in many settings, and switching depends on local cost and operational fit.
Regulatory and supply chain friction: Sterile/packaging requirements, labeling language, and distribution constraints can slow scaling even when demand exists.

How does KRINTAFEL pricing typically behave across malaria-endemic markets?

Pricing for malaria therapies is usually benchmarked through:

tender-based procurement (often lowest-cost or most-favorable contract terms),
donor-funded procurement (PAHO/UN agencies and global health buyers), and
government price controls in certain geographies.

For tafenoquine, the economic model tends to follow a “contract pricing” pattern rather than consumer-style list pricing.

Pricing dynamics that matter for forecasting

Tender compression: Over time, winning bids tend to set a lower market clearing price for future cycles.
Formulary leverage: Programs that standardize on one regimen can lock in supply pricing but also create predictable replacement opportunities when contracts rebid.
Shelf-life and logistics terms: Effective cost to the buyer includes distribution SLAs, packaging compatibility for program logistics, and replacement clauses.

When does KRINTAFEL face generic entry risk under U.S. and EU exclusivity?

Generic entry risk depends on the patent estate and data exclusivity status, which in turn is driven by:

the active-ingredient and composition patent families for tafenoquine,
any formulation patents for the specific product (dosage form, tablet strength, excipient system),
and any method-of-use patents tied to dosing schedules or safety steps.

Practical entry-likelihood framework for high-stakes planning

If core compound or key formulation claims expire soon: challengers can file sooner and schedule launch once exclusivity ends.
If Orange Book-relevant patents remain listed: generic launch may be blocked absent resolution via settlement, license, or successful invalidity/ non-infringement arguments.
If only method-of-use patents remain: entry risk is more about label carve-outs and “skinny label” strategies.

Exclusivity calendar logic for tafenoquine brands

In most malaria drug brand models, exclusivity risk accelerates when:
1. listed patents covering the branded label strategy approach expiration, and
2. the buyer market shifts to tenders that reward unit cost more aggressively.

Because this response must remain complete and accurate, it cannot map exact KRINTAFEL expiration dates without the KRINTAFEL-specific patent list and regulatory dossier data.

What is the competitive landscape for relapse prevention of P. vivax and where does tafenoquine fit?

Tafenoquine competes primarily with:

primaquine-based relapse prevention regimens (including operationalized dosing schedules), and
other malaria chemotherapies used in P. vivax management depending on country protocols.

Competitive positioning that shapes revenue

Adherence and supervision: Tafenoquine’s dosing simplicity can reduce reliance on multi-day supervision, which is a procurement and implementation advantage.
Clinical comfort versus safety constraints: Clinician adoption can lag if the safety workup is perceived as heavy.
Program standardization: Once national protocols lock into a regimen for procurement convenience, switching costs rise.

Where revenue tends to shift

Initial adoption regions: often where national programs can run G6PD testing and where guideline updates are rapidly converted into tender specs.
Sustained share regions: where procurement cycles favor contract continuity and where buyers accept tafenoquine’s safety requirements.
Erosion regions: where primaquine remains cheap and the program has limited diagnostic capacity.

How do manufacturing and supply constraints affect KRINTAFEL revenue trajectory?

Malaria drug supply chains are sensitive to:

active pharmaceutical ingredient sourcing,
API and intermediate capacity,
tablet manufacturing slots,
and packaging suitable for heat, humidity, and long distribution lanes.

Supply-side levers

Lead times from tender award to shipment: delays compress quarterly revenue and push bookings into later periods.
Batch availability and QA release: shortages can temporarily throttle demand even when prescriptions exist.
Regulatory batch release requirements: post-approval changes, line upgrades, or site transfers can introduce lead-time risk.

For revenue forecasting, supply constraints often explain “lumpy” results more than demand swings do.

What formulation and method-of-use patents would block lower-cost KRINTAFEL alternatives?

For tafenoquine brands, infringement risk typically concentrates in three clusters:

Composition and formulation claims

tablet formulation and excipient systems,
specific dosage strength(s) and manufacturing method constraints,
stability and dissolution-linked formulation attributes.

Method-of-use claims

relapse prevention dosing schedule,
patient-selection rules tied to safety management frameworks,
G6PD testing-linked prescribing steps when those steps are claimed as part of the method.

How label design changes work as a countermeasure

Lower-cost entrants often attempt to:

change the label dosing language,
narrow patient eligibility,
or pursue “carve-out” positions that avoid claimed method elements.

This is why method-of-use IP often has outsized commercial impact relative to compound claims, even when the active ingredient is old.

What patent litigation and settlements typically affect KRINTAFEL commercialization?

In generic entry pathways, the litigation pattern is usually:

Paragraph IV or equivalence disputes in the U.S.,
or similar oppositions and challenges in the EPO route,
followed by settlement agreements that can delay launch.

However, this response cannot cite or describe KRINTAFEL-specific litigation and settlement terms without a verified record of the exact case docket(s), asserted patents, and parties.

What is the FDA regulatory status of KRINTAFEL and how does it shape access?

Commercial trajectory depends on:

approval status and label scope,
REMS or safety monitoring requirements (if any),
and whether supplemental approvals expand eligible populations or dosing guidance.

Tafenoquine access in the U.S. can also influence international credibility for procurement organizations, but the dominant determinant for revenue in malaria is still government and donor purchasing.

This response cannot map KRINTAFEL’s exact FDA label history, supplemental approvals, or Orange Book listings without verified source data tied to KRINTAFEL specifically.

How many patents cover KRINTAFEL and who holds the IP?

A complete “how many patents” count requires the KRINTAFEL-specific patent list across:

relevant jurisdictions (U.S., EU, and key local markets),
all assignees in the tafenoquine family,
and whether those patents are composition, formulation, or method-of-use.

This response does not provide those counts because it would be incomplete or potentially inaccurate without the KRINTAFEL patent listing set.

What generic entry risks exist for KRINTAFEL and what launch scenarios are plausible?

For planning purposes, generic entry scenarios typically fall into three buckets:

Full generic launch immediately after exclusivity: requires that no listed patents remain enforceable for the branded label.
Launch with label carve-outs: reduces claimed method infringement risk, limiting usable patient populations and lowering share.
Delayed launch via settlement or injunction: keeps the brand exclusive longer, often tilting revenue further into later years.

Tafenoquine’s real-world competitive impact is likely larger when entrants can:

support G6PD testing operational workflows,
and offer contract pricing that passes tender scrutiny.

Without the verified KRINTAFEL exclusivity and patent landscape, the specific timing and plausibility ranking cannot be stated accurately.

How does KRINTAFEL compare with primaquine on commercial and access economics?

Brand-level commercial differences

Operational load: Primaquine often requires multi-day adherence support. Tafenoquine’s single-dose positioning can reduce program burden.
Safety workflow: Both require safety assessment, but tafenoquine’s eligibility constraints can reduce the effective market.
Procurement behavior: Buyers that optimize delivery logistics may favor tafenoquine, while cost-minimizing programs may default to primaquine.

Market share implications

Tafenoquine tends to win where programs can reliably perform G6PD testing and where adherence programs exist or where supervision burden is high.
Primaquine tends to hold where diagnostic capacity is limited or where tender costs dominate.

Key performance indicators investors track for KRINTAFEL revenue trajectory

For a malaria therapy, high-signal KPIs include:

government and donor contract revenue share (vs. private markets),
tender win rate and average contracted unit price,
inventory turns and fill-rate (supply continuity),
geographic concentration (top-country dependence),
G6PD testing capacity proxy (often correlated with adoption pace),
cycle-time from tender award to first shipment.

Key Takeaways

KRINTAFEL’s market dynamics are driven less by broad therapeutic substitution and more by country program protocols, G6PD testing readiness, and tender-based procurement.
Revenue trajectory is typically “contract-cycle shaped,” with quarterly volatility influenced by award-to-shipment timing and supply continuity.
Competitive pressure is likely to emerge through lower-cost tafenoquine alternatives and label strategies that mitigate method-of-use infringement, as well as through continued reliance on primaquine in settings where testing capacity is limited.
Exact exclusivity timelines, patent counts, and litigation outcomes cannot be stated here without verified KRINTAFEL-specific patent and regulatory listing records.

FAQs

1) What determines KRINTAFEL adoption for P. vivax relapse prevention in endemic countries?
Guideline inclusion, available G6PD testing workflow, procurement tender specifications, and clinician comfort with safety eligibility rules.

2) How do donor tenders influence KRINTAFEL pricing and unit volumes?
Donor purchasing often sets contract unit economics and creates predictable repeat cycles that can compress pricing if competitors underbid.

3) Does KRINTAFEL compete more with drug cost or with program execution burden?
Both, but program execution burden (testing, supervision, adherence logistics) can be a decisive factor when it changes delivery feasibility.

4) What is the most sensitive variable in forecasting tafenoquine brand sales?
Shipment timing relative to tender cycles and the ability to maintain consistent supply and QA release.

5) What generic entry strategy most threatens KRINTAFEL?
A lower-cost tafenoquine product that can support label-relevant use and operational safety requirements without losing eligibility share to carve-outs.

References (APA)

No sources were cited because the response requires KRINTAFEL-specific patent, exclusivity, litigation, and regulatory listing data to be complete and accurate.

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	104
Clinical Trials:	1
Patent Applications:	588
Drug Prices:	Drug price information for KRINTAFEL
What excipients (inactive ingredients) are in KRINTAFEL?	KRINTAFEL excipients list
DailyMed Link:	KRINTAFEL at DailyMed

Sponsor	Phase
Mahidol Oxford Tropical Medicine Research Unit	Phase 4
Shoklo Malaria Research Unit	Phase 4

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Glaxosmithkline	KRINTAFEL	tafenoquine succinate	TABLET;ORAL	210795-001	Jul 20, 2018		RX	Yes	Yes	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

KRINTAFEL Drug Patent Profile

Which patents cover Krintafel, and when can generic versions of Krintafel launch?

AI Deep Research

Questions you can ask:

Summary for KRINTAFEL

Recent Clinical Trials for KRINTAFEL

US Patents and Regulatory Information for KRINTAFEL